MARKET

VRDN

VRDN

Viridian Therapeutics Inc
NASDAQ
16.82
-0.61
-3.50%
After Hours: 16.80 -0.02 -0.12% 19:58 05/15 EDT
OPEN
17.26
PREV CLOSE
17.43
HIGH
17.38
LOW
16.71
VOLUME
1.61M
TURNOVER
--
52 WEEK HIGH
34.29
52 WEEK LOW
12.07
MARKET CAP
1.86B
P/E (TTM)
-4.2498
1D
5D
1M
3M
1Y
5Y
1D
Viridian Therapeutics Price Target Cut to $26.00/Share From $27.00 by Evercore ISI Group
Dow Jones · 1d ago
Viridian Therapeutics Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 1d ago
Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $26
Benzinga · 1d ago
Evercore ISI Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)
TipRanks · 1d ago
Fairmount Healthcare Fund II buys 1,176,470 Viridian shares for $20 million
PUBT · 3d ago
Viridian Therapeutics price target lowered to $39 from $48 at Stifel
TipRanks · 3d ago
Viridian Therapeutics Raises $359 Million in Offerings
TipRanks · 4d ago
Viridian prices USD 250 million 1.75% convertible notes due 2032
PUBT · 5d ago
More
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Webull offers Viridian Therapeutics Inc stock information, including NASDAQ: VRDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRDN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRDN stock methods without spending real money on the virtual paper trading platform.